Literature DB >> 16977589

Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study.

Effat Souri1, Hassan Jalalizadeh, Abbas Kebriaee-Zadeh, Maral Shekarchi, Afshin Dalvandi.   

Abstract

A new, simple, and reproducible method for determination of carboxylic acid metabolite of clopidogrel in human plasma has been developed. After liquid-liquid extraction in acidic medium with chloroform, samples were quantified on a Nova-pak C(8), 5 microm column using a mixture of 30 mM K(2)HPO(4)-THF-acetonitrile (pH = 3, 79:2:19, v/v/v) as mobile phase with UV detection at 220 nm. The flow rate was set at 0.9 mL/min. Ticlopidine was used as internal standard and the total run time of analysis was about 12 min. The method was linear over the range of 0.2-10 microg/mL of clopidogrel metabolite in plasma (r(2) > 0.999). The within-day and between-day precision values were in the range 1.0-4.8%. The limit of quantification of the method was 0.2 microg/mL. The method was successfully used to study the pharmacokinetics of clopidogrel in healthy volunteers. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16977589     DOI: 10.1002/bmc.697

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  6 in total

1.  A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma.

Authors:  Cody J Peer; Shawn D Spencer; Dustin A H VanDenBerg; Michael A Pacanowski; Richard B Horenstein; William D Figg
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-11-26       Impact factor: 3.205

2.  Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions.

Authors:  Helena Leonie Hanae Loer; Denise Türk; José David Gómez-Mantilla; Dominik Selzer; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2022-04-22       Impact factor: 6.525

3.  The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study.

Authors:  Ali Reza Khosravi; Masoud Pourmoghadas; Mohammad Ostovan; Gilda Kiani Mehr; Mojgan Gharipour; Habib Zakeri; Bahram Soleimani; Mehrdad Namdari; Mehdi Hassanzadeh; Ali Akbar Tavassoli; Samad Ghaffari; Arsalan Khaledifar; Farshad Roghani; Mohammad Reza Khosravi; Shahrooz Sarami; Javad Kojouri; Fatemeh Nori; Elham Khosravi; Mahnaz Jozan; Nizal Sarrafzadegan
Journal:  J Res Med Sci       Date:  2011-05       Impact factor: 1.852

4.  Development of a new HPLC method for simultaneous determination of clopidogrel and its major metabolite using a chemometric approach.

Authors:  V Anuta; I Sarbu; I Mircioiu; B S Velescu
Journal:  Curr Health Sci J       Date:  2015-03-15

5.  Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention.

Authors:  Urszula Adamiak-Giera; Anna Czerkawska; Szymon Olędzki; Mateusz Kurzawski; Krzysztof Safranow; Maria Jastrzębska; Barbara Gawrońska-Szklarz
Journal:  Pharmacol Rep       Date:  2020-12-03       Impact factor: 3.024

6.  In vitro inhibition of platelets aggregation with generic form of clopidogrel versus branded in patients with stable angina pectoris.

Authors:  Rza Hajizadeh; Samad Ghaffari; Mojtaba Ziaee; Behrooz Shokouhi; Ahmad Separham; Parvin Sarbakhsh
Journal:  J Cardiovasc Thorac Res       Date:  2017-10-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.